Brochure
15 Sep 2021

Find out more about Aptar Pharma Services

PDF 3.7 MB

Our specialist analytical, laboratory and regulatory services add value at every stage of the drug development process, accelerating and de-risking your program along the way.

Content provided by our supplier

Aptar Pharma

  • FR
  • 2015
    On CPHI since
  • 5000+
    Employees
Company types
Packaging supplier/manufacturer

Other Content from Aptar Pharma (39)

  • Sponsored Content Sustainability and digital adoption among trends shaping pharma packaging and drug delivery 

    The pharma packaging and drug device industry is constantly evolving to optimise drug delivery, keep up with medical advances and ensure regulatory compliance. Trends like sustainability, cost-efficiency and digitisation continue to shape the sector, and the COVID-19 pandemic remains a challenge.  
  • Brochure Intranasal Immunization: Promises and Challenges

    Today, there are three marketed nasal vaccines available for human use but many more are in development for both human and veterinary use.Nasal vaccination provides an alternative to the more conventional Injectable drug delivery system. Mucosal immunity can develop via interaction with immune modulators present in the nasal cavity, where the nasal associated lymphoid tissue (NALT) region plays a dominant role
  • News Aptar Pharma Partners with Stallergenes Greer to Develop Novel Digital Health Ecosystem for Allergen Immunotherapy Treatment

    The innovative, easy-to-use connected drug delivery device and companion mobile app will contribute to improving dose compliance and adherence, thus optimizing patient treatment outcomes.
  • Brochure Ocular Drug Delivery: an Interesting Past with a Fascinating Future Webinar

    Ophthalmic diseases such as Age-related Macular Degeneration (AMD) and Glaucoma are potentially chronic conditions, requiring life-long medical therapy. Failure by the patient to adhere to a proper treatment regimen may lead to disease progression and visual loss, in addition to all of the consequences around quality of life and capacity to work.
  • News First Nasally-Administered Pharmaceutical Treatment for Dry Eye Disease Approved by US FDA with Aptar’s Nasal Pump System

    Aptar Pharma’s patented Cartridge Pump System (CPS), was recently reviewed by the U.S. FDA as the drug delivery device in the approval of Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray 0.03 mg, the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease.
  • Brochure PureHale Brochure

    PureHale Technology Platform

    Better Breathing Made Easy


  • News Aptar Pharma and i2c Pharmaceutical Services Partner for Next Generation Propellant Dispersible Tablet pMDI technology

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, and i2c Pharmaceutical Services, a leading service provider for the development of pharmaceutical formulations, today announced an exclusive partnership to co-develop and promote i2c’s patented pressurized metered dose inhaler (pMDI) technology, Respitab®.
  • Brochure Aptar Pharma is the go-to drug delivery expert

    We design, develop and manufacture a comprehensive range of innovative and patient-focused drug delivery systems, services and proven solutions for the widest range of biotechnology, healthcare and pharmaceutical applications.
  • News Aptar Announces the Signature of a Share Purchase Agreement Regarding the Acquisition of a Majority Stake in Voluntis at a Price of €8.70 per share

    Aptar announced today that following the entry into exclusive negotiations with Voluntis (ENXTPA: ALVTX) on June 21, 2021, and after completion of the consultation procedure of the employee representative bodies of Voluntis, it has signed on July 22, 2021 a share purchase agreement for the acquisition...
  • News Aptar Pharma Granted Exclusive License Option by Pharmaxis to Develop and Promote High Payload Dry Powder Inhaler

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced that they have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital.
  • News Top 5 Industry Content Reads on CPHI Online This Month

    If you’re looking for news, product information and market trends from leading pharma companies, the CPHI-Online.com Company Showcases are a great resource for buyers who want to stay up to date, browse product portfolios and find the right partner.

  • News Aptar Pharma partners with Sonmol on digital platform for respiratory-related therapies

    The collaboration will focus on bringing together connected drug delivery devices and the digital platform for asthma and COPD in China and other Asian markets.
  • News FDA approves Unidose device for new nasal seizure rescue treatment

    The single-use, ready-to-use, one-step nasal delivery device can deliver a formulation in an emergency situation quickly and easily.
  • Brochure Successfuly balancing the needs of the planet with the needs of the patient

    In this article, Christophe Marie, Global Product Sustainability Director, and Taylor Price, Manager, Global Sustainability, both at AptarGroup, and Julien Storz, Director of Business Development, Consumer Healthcare, at Aptar Pharma, chart the commitments and progress made to date by Aptar in achieving its sustainability targets. The authors also provide examples of integrated, circular economy initiatives undertaken by Aptar Pharma at a product solution level and comment on concrete commitments that can be made to further progress towards sustainability.
  • News Aptar acquires a leader in drug delivery training devices and patient onboarding

    Acquisition reflects movement of treatments being administered by patients at home rather than by healthcare providers.
  • Whitepaper Digital Healthcare Solutions

    In these short interviews, Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.
  • News Aptar Acquires Noble International, a Leader in Drug Delivery Training Devices and Patient Onboarding

    AptarGroup, Inc. (NYSE: ATR), a global leader in consumer dispensing, active packaging and drug delivery solutions, announced today that it has acquired Noble International, a leader in drug delivery training devices and patient onboarding.
  • Whitepaper Is Now The Time to Shake up The pMDI Environment

    A review on how the use of propellants in pressurized metered dose inhalers has evolved and how alternative propellants, such as more environmentally friendly propellants, could be a catalyst for greater patient adherence.
  • News FDA approves Activ-Blister packaging solution for oral solid dose HIV prevention medicine

    The system protects oral solid drug products with a 3-Phase Activ-Polymer solution that is fully integrated into the blister package.
  • Video Discover the Top 10 reasons to partner with Aptar Pharma

    Aptar Pharma thrives on transforming ideas into commercial opportunities, bringing drug delivery solutions to market for customers around the world. Discover how we can help you with your next drug delivery challenge.
  • News Unidose device approved for Tosymra sumatriptan spray

    Provides migraine sufferers with a convenient, patient-friendly delivery approach.
  • Video Explore 2021 Aptar Pharma’s virtual booth to discover why we are the go-to drug delivery expert

    Discover why Aptar Pharma is the go-to drug delivery expert. Our life-life virtual booth is rich in content, featuring 3D products, multi-media videos, brochures, scientific publications and more for you to experience. Hover your mouse cursor over the colored circle hotspots to uncover and interact with our broad range of complete product and service solutions. Enjoy an enhanced virtual visitor experience, and be sure to book a meeting with one of our Aptar Pharma experts to find out how we can help you solve your next drug delivery challenge. To visit our virtual booth, click the “Download” button
  • News FDA approves Aptar's needle-free rescue treatment for severe hypoglycemia

    Aptar’s nasal Unidose device - the result of a 10-year customer collaboration - marks the first FDA approval of a prescription drug using the company’s patented Unidose Powder System.
  • Video Intranasal Immunization: Promises and Challenges

    This webinar originally aired as part of CPHI Discover - 17-28 May 2021 Nasal spray drug delivery can provide significant advantages over traditional approaches to vaccine administration. In this session, hear from Aptar Pharma and Vaccine Market Review on nasal physiology and Vaccine targets.  This session will serve as an introduction to Aptar Pharma and Vaccine Market Review nasal physiology and vaccine targets. Discussion points include: Overview of intranasal formulations Review nasal vaccine Opportunities Aptar Pharma device offerings
  • News Aptar Pharma and Lovelace Biomedical to Host Webinar on “New Tools to Advance CNS Drug Delivery”

    Aptar Pharma, a leading drug delivery systems provider, will host a live educational webinar reviewing new methodologies in assessing CNS drug deliveries. Taking place on July 17 at 3pm GMT, the webinar, entitled “New Tools to advance CNS Drug Delivery”, will be hosted by Dr. Julie D. Suman, President of Next Breath, an Aptar Pharma business, and Dr. Philip Kuehl, Senior Scientist, Lovelace Biomedical.
  • Video Drug Repurposing: A more Efficient Approach to Drug Development?

    This webinar originally aired as part of CPHI Discover - 17-28 May 20211. Drug repurposing has gained traction in the past year amidst the COVID-19 vaccine race - what are the challenges & potential benefits of drug repurposing, compared to the traditional drug development process? What is drug repurposing? Benefits to the development process- speed to market, risk, costs Advantages of nasal delivery and the challenges of repurposing Patient benefits -Our track record and case study Case Study: Repurposing Generic Drugs for COVID-19 and Cancer Using AI-Powered Technology
  • News New portable and ready-to-use upper respiratory drug delivery solution

    PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.
  • Video Develop a Novel Concept for Nasal and Pulmonary Drug Delivery

    There are several key strategic decisions to be made in the rapid development process of COVID-19 vaccines and treatments, including where to target the drug delivery, the appropriate formulation, the correct device and the best regulatory pathway. This webinar discusses these challenges for nasal and pulmonary drug delivery.
  • News Aptar Pharma to showcase an industry first

    PureHale is a new portable drug delivery device designed for upper respiratory care.
  • Video PureHale by Aptar Pharma - Better Breathing Made Easy

    The industry’s first cordless, ready-to-use, nebulizer-like system

    PureHale™ is a cordless, nebulizer-like device that comes pre-filled and allows users to relieve their symptoms wherever and whenever needed.

  • News French ANSM approves Aptar's Ophthalmic Squeeze Dispenser

    Approval expands the regulatory acceptance of Aptar Pharma’s OSD as an approved delivery system for preservative-free eye care formulations.
  • Video Aptar Pharma's Ophthalmic Squeeze Dispenser (OSD) clearly the world's favorite

    Aptar Pharma’s Ophthalmic Squeeze Dispenser is the leading device for preservative-free prescription and over-the-counter products. Featuring unrivaled microbiological safety and a proven track record with more than  300 market references worldwide, it is the only FDA-reviewed technology for multidose, preservative-free systems in eye care

  • Video How Digital Healthcare Solutions Could Improve Patient Compliance and Adherence

    When patients self-administer their medications, 60% do not take them as intended and over half of all patients are non-adherent. The resulting cost of non-adherence and non-optimized therapy is steep and everyone pays the price, from Pharmaceutical companies and payers to HCPs and their patients. The cost of non-adherence alone is US$300 billion per year with $188 billion of US pharma revenue lost. Aptar provides a broad range of Digital Healthcare disease management solutions that are ideal for patients who will self-administer their medications. Our technology has the potential to augment patient care, deliver value across the digital health ecosystem and deliver better patient outcomes providing a more seamless engagement for HCPs, payers, and our Pharma partners in a more connected future.This webinar originally aired as part of Pharmapack Europe 2021
  • Webinar Striving for a More Circular Industry - How Aptar Pharma can Support your Sustainability Journey

    In this webinar, originally broadcast as part of the Pharmapack Europe show, speaker Christophe Marie, Global Product Sustainability Director, Aptar Pharma discusses how key Pharmaceutical players are acknowledging that caring for human health is closely tied to caring for the health of the planet. However, the nature of the global Pharma business makes this a challenge to accomplish without collaboration from the full value chain. Aptar Pharma, a key partner to the Pharmaceutical industry, is committed to furthering a more sustainable business. During his Learning Lab presentation Christophe Marie will share how Aptar is addressing the challenges of sustainability and the aspirations, goals and targets that can support a more sustainable pharmaceutical industry. Additionally, he will outline what pioneering solutions will have the potential to evolve pharmaceutical packaging and support circular economy. This session was broadcast as part of the Pharmapack show.
  • Webinar Connected Devices, Digital Health and Digital Therapeutics: Where are We Heading and Why?

    In this webinar, originally broadcast as part of the Pharmapack Europe show, speaker Marcus Bates, Vice President, Digital Healthcare, Aptar Pharma covers an introduction to Connected Devices and the different therapeutic areas that they touch. He also reviews the interaction and interoperability between the connected device and the software platform. He discusses the need for clear definition of the intended use and how this will drive the claims which ultimately leads to the regulatory classification. He also reviews the regulatory classification, regulatory hurdles and the importance of building a road map enabling Real World Data generation. Finally, we will discuss the value and ROI for Connected devices, the most advanced countries for regulatory and reimbursement pathways.
  • Webinar Benefits of Nasal Drug Delivery – More than just Hay Fever

    In this webinar, speaker Gemma Budd, Director of Business Development, Nanopharm, will highlight the considerations for both systemic/N2B and intranasal vaccines, and the differences in approach when designing the best device and formulation combination. This session was originally broadcast as part of the Pharmapack Europe 2022. Nasal sprays have been around for decades to successfully manage conditions such as allergic rhinitis (hayfever), where treatment of the nasal cavity is the target. Locally acting nasal drug products continue to be developed to treat other infectious diseases, with a big focus on biologic molecules. Furthermore, the COVID-19 pandemic has accelerated the interest in intranasal vaccine administration to enable rapid roll out of vaccines with fewer supply chain challenges for respiratory diseases, and these products target the NALT region of the nose. By contrast, due to the potential for enhanced and rapid bioavailability, there is resurgence of interest in intranasal delivery to treat systemic disease, and particularly CNS indications, where direct nose-to-brain (N2B) delivery via targeting the olfactory region of the nose.